Gabelli & Co. is raising its estimates on Johnson & Johnson JNJ following earnings yesterday.
In a note to clients, Gabelli writes, "We have raised our 2011 EPS estimate by $0.10 to $4.95 due to FX rates, a favorable Merck settlement, and core business strength.
JNJ reported an impressive quarter which could mark the beginning of a long-awaited acceleration in revenue and earnings as pharma and device businesses perform well and the impact of the OTC recalls begins to fade.
PMV of $80 in 2012"
Shares of JNJ are up $1.17 to $63.86, a gain of 1.8%.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in